Effect of body gamma knife on immune microenvironment of MSS/pMMR solid tumor and its application in comprehensive therapy

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200066117

Enrollment

Unknown

Registered

2022-11-24

Start date

2022-12-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid malignant tumor

Interventions

One arm test:Body gamma knife therapy(SBRT)+ Immunotherapy + Targeted therapy + chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18 and 80 years with solid tumors; 2. Tissues were obtained by colonoscopy, bronchoscopy, surgery or puncture in the early stage, histological or cytological evidence was confirmed by definite pathological diagnosis, and MSS/pMMR solid tumor was confirmed by PCR, Nanostring and/or immunohistochemistry. Relevant evidence data should be provided; 3. KPS >= 60PS =2000/µl;Neutrophil >=1000/µl; Blood cells >= 75,000 /µl; Hemoglobin >=75 gl/l; 6. Liver function (serum total bilirubin =40 ml/min); 8. Coagulation function (international standardized ratio or prothrombin time <=1.5×ULN time to activate partial thrombin <=2.5×ULN); 9. A definite number and measurable size of metastases or bone metastases in a definite location; 10. Patients with inoperable or operable cancer foci who refuse surgical treatment; 11. Participants did not take hormonal medications for 7 days prior to treatment; 12. No previous radiation therapy; 13. Sign the subject's written informed consent to join the clinical trial.

Exclusion criteria

Exclusion criteria: 1. The number and size of tumor lesions cannot be evaluated; 2. Patients with contraindications of chemoradiotherapy, targeted therapy and immunotherapy; 3. Patients with active autoimmune and/or psychiatric disorders; 4. Received treatment in other clinical trials within 4 weeks prior to initial administration; 5. Pregnant or lactating female patients.

Design outcomes

Primary

Measure	Time frame
Changes in the size and number of cancer foci;Progression-free survival;Overall survival;Changes in the immune microenvironment;	—

Secondary

Measure	Time frame
Security;	—

Countries

China

Contacts

Public ContactYunlong Pan

The First Affiliated Hospital of Ji'nan University

tpanyl@jnu.edu.cn+86 13380095698

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026